Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you so much for your tirelessly warnings for us gamblers about KALY garbage scam. I just wish I had your email so I could e-transfer you a boatload of money to show my appreciation when I make tons of money from other garbage scam stocks.
this company garbage ,call the number go to the address..
any extension you call will be busy . they will never call you back ....you wanna a good laugh go to the address....
these crooks do not anything period....it was a scam,
A better question: Why are YOU here at all ?
Why are there any buyers here at all. What direction> Find another scam.
Shareholders would like to know when we will receive PAOG shares for our pain and suffering of holding KALY shares.
Maybe someone would be kind enough to update what direction the company is headed in currently?
Im sure its top secret technology based, where we should just hold our shares based on the reputation of the company.
Shareholders would like to know when we will receive PAOG shares for our pain and suffering of holding KALY shares.
Maybe someone would be kind enough to update what direction the company is headed in currently?
Im sure its top secret technology based, where we should just hold our shares based on the reputation of the company.
this should be 000s next week they don't have crap ..
no legit product, no legit number ...
PURA sold NCM Biotech (grow houses) to PAOG and ONE product developed with this extraction technology that must be good. All backed by major funds.
$kaly $0.0013 ? 0.0 (0.00%)
Volume: 1,768,485 @08/27/20 11:40:22 AM EDT
PAOG shares for selling off part of KALY? How Many shares, What timetable?
$KALY PATENTED EXTRACTION PROCESS STILL IN PLACE!!!!
$PAOG purchased RespRx. ONE PRODUCT....
kaly in the stealing business......they made tons and now it done.
they have no clue what new scam to do imho....
you have to call your broker to buy it ,its so bad .
The NCM Biotech sale marks an exit from the cannabis industry for KALY. The company has already developed a new business direction. The NCM Biotech sale to PAOG is expected to be complete by the end of July. KALY plans to announce its new business direction, which is already underway, in conjunction with the closing of the deal with PAOG.
NO follow up, End of July?, Did it fall through? No update of new business direction, No PAOG shares issued in my account?
Agreed in the Macro world.
However, I would like in the Micro world, just a update from our CEO what business we are in, what direction is so exciting that we made a 180?
do your dd . send them an email and call these crooks you wont get a response on either one they will run this pile to the ground .0001 then shut the doors .
no office, no product, they don't even have a legit number its an answering service .....press any extensions TOU WONT GET JACK CHIT...
Here's some DD for you... FDA IS OUT???
There are still market uncertainties for our nascent industry, and it is critical to open end markets for our crops. The Administration could play a crucial role by resolving the regulatory barrier created by FDA that has prevented FDA from recognizing cannabidiol (CBD) as a legitimate botanical ingredient for use in food and dietary supplement products. Any support for a legislative solution in removing this regulatory burden would be sincerely appreciated.
https://www.reginfo.gov/public/do/eoDownloadDocument?pubId=&eodoc=true&documentID=6945
yes but I hear the share count is in the billions.
try emailing them or calling them . they will never return your emails or phone calls ....
I don't think they even have an office or a product ,imho just another scam .....
unless they prove otherwise just from what I have look into and all my dd....
MAKE THAT CALL OR EMAIL THEM YOU WILL SEE
Your DD needs to include reading the dates if you want to use correct information to get everyone on board
KALY – Kali-Extracts Confirms Second Bid On Its Cannabis Biopharmaceutical Technology Valued At $50 Million
11/12/2019 | 09:40am
DALLAS, Nov. 12, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed a second party has approached the company to express interest in acquiring KALY’s U.S. Patented Cannabis Extraction Process and related biopharmaceutical technology valued at $50 million. KALY recently announced entering into discussions with a first investor to explore a possible sale of KALY’s cannabis biopharmaceutical technology. The first investor valued the technology at $50 million. KALY management considers the valuation consistent with Goldman Small Cap Research’s recent valuation, but management maintains a position that the valuation still does not reflect the full potential of its intellectual property. The second party expressing interest has not yet communicated the value it places on KALY’s U.S. Patented Cannabis Extraction Process and related biopharmaceutical technology. KALY management indicates it is only entertaining opportunities where KALY management remains involve in the ongoing development of the cannabis biopharmaceutical technology and where KALY maintains rights to the patent in support of its ongoing edible and beverage business as well as in support of its ongoing hemp farming CBD extraction business.
KALY management indicates it is only entertaining opportunities where KALY management remains involve in the ongoing development of the cannabis biopharmaceutical technology and where KALY maintains rights to the patent in support of its ongoing edible and beverage business as well as in support of its ongoing hemp farming CBD extraction business. 11/2019.
https://www.marketscreener.com/amp/quote/stock/KALI-INC-27113391/news/KALY-ndash-Kali-Extracts-Confirms-Second-Bid-On-Its-Cannabis-Biopharmaceutical-Technology-Valued-A-29566542/
It a share scam never gonna see it no paperwork filed with sec
has anyone received shares from
METAVERSE CAP CORP F**RESTRICTED STOCK**
as part of the deal kali made with pura or poag?
says who? oh yeah the SCAM ITSELF LOL
"acquired proprietary formulations" Patent still in place. $KALY
As part of the KALY transaction, PAOG acquired the proprietary formulations derived from a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” KALY’s research and ongoing pharmaceutical developments were part of the acquisition.
It should be noted that KALY was engaged with a number of different universities on a variety of separate research initiatives, such as the University in Kentucky on the COPD study.
https://www.goldmanresearch.com/202008131283/Opportunity-Research/under-the-radar-cbd-pharma-player-could-offer-major-upside.html
that is not news hahaha., THAT IS PAID PROMOTION., BUT I MEAN PAIDDDDDDD PROMOTION.. THAT IS NOT NEWS LOL
NEWS.....
PAOG - Under the Radar CBD Biopharma Player Could Offer Major Upside
NCM Biotech May be in the works of developing some kind of Covid treatment for the Pandemic We are Currently Facing. NCM Biotech according to information posted on the webpage has already reached out to the Bill & Melinda Gates Foundation Please Review the DD below and understand what is NCM Biotech and why it is important that this deal closes tomorrow.
How many more ResRx type patents does Kali Extracts have?
RespRx is a treatment for Chronic Obstructive Pulmonary Disease (COPD) under development that is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
The market for COPD treatment is anticipated to reach $14 billion by 2025.
A patent application on the RespRx formulation for symptoms associated with COPD and other similar respiratory conditions has been filed. A trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions has also been filed.
Caveat Emptor
Buyer Beware. OTC Markets Group has determined that there is a public interest concern associated with the company, which may include a spam campaign, questionable stock promotion, known investigation of fraudulent activity committed by the company or insiders, regulatory suspensions, or disruptive corporate actions.
KALY sold ONE PRODUCT... Patent still in place!!!!!!!!!!
Kali-Extracts (USOTC: KALY). A number of treatments derived from the patented cannabis extraction operation are under development.
hahaha look at that dumping today no ask slaps for this SCAM
No. KALY has zero. Just offshore indicted principles working under other pawns who have all now also been indicted.
Shame as it is nothing but a black eye and serious credibility hit. EverX is a disaster, PURA is in dire straights. So you have connected companies that are all garbage and the can never get away from the worst of them all KALY.
More blatant lies. Halting of trading, more investigations, more dragging other Companies down with them.
Sandusky, Ohio--(Newsfile Corp. - August 6, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon is scheduled for release tomorrow, August 7, 2020. Mr. DiPrima also appeared on MoneyTV last week following PAOG's acquisition of two medical cannabis companies.
Are we expecting anything soon from kali?
North American Cannabis Holdings, Inc. (US:USMJ) has 1 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 999,999 shares. Largest shareholders include Cornercap Investment Counsel Inc.
Cornercap Investment Counsel Inc. 1.3 Billion current assets.
https://fintel.io/so/us/usmj
USMJ developed and spun off what is today Puration (PURA), the leading producer of a hemp-derived CBD infused sports beverage called EVERx. The work with EVERx advanced by a patented cannabis extraction process which is today housed under the company Kali-Extracts (KALY).
USMJ was formed to develop this partnership. They will always be involved with any of the others accomplishments.
What is the terms of the sale, shareholders might be interested in knowing
$kaly $0.0017 v -0.0001 (-5.56%)
Volume: 1,973,338 @07/31/20 3:56:57 PM EDT
I heard they are taking over the Bluth family Banana Stand. Should be a great change for them.
The acquisition of RespRx is an all stock deal. PAOG has purchased RexpRx from KALY for common stock. PAOG remains in negotiations with KALY about a potential comprehensive acquisition of the underlying patent from which the RespRx formula was derived.
Looks like Fredrick(KALY) is keeping the patent, that means he still believes it could be the holy grail.
If KALY has a cure for cancer with a patent then why would they sell the biggest advance in medical history to a scam like PAOG?
KALY plans to announce its new business direction, which is already underway, in conjunction with the closing of the deal with PAOG.
https://www.otcmarkets.com/stock/KALY/news/story?e&id=1646623
PAOG has purchased RexpRx from KALY for common stock.
PAOG remains in negotiations with KALY about a potential comprehensive acquisition of the underlying patent from which the RespRx formula was derived.
Today is the day, Kaly sells technology and research of years to PAOG and we go in another direction to be announced. Fredrick cant take it to the next level? Fredrick has found a new direction of something more profitable? Fredrick is a bored and wants a new challenge?
Place your Bets looking for NEWS TODAY
6 months ago...
NCM BIOTECH issued provisional Patent for COPD Treatment
?
NCM BIOTECH Founder and President, Frederick Ferri, is very pleased to announce that NCM BIOTECH has been issued a provisional Patent for their ground breaking COPD Treatment. Under United States patent law, a provisional application is a legal document filed in the United States Patent and Trademark Office. Fredd is excited to work toward an issued patent over the next year.
Please keep checking back on our Patent Status.
KALY plans to announce its new business direction, which is already underway, in conjunction with the closing of the deal with PAOG.
https://www.otcmarkets.com/stock/KALY/news/story?e&id=1646623
Followers
|
315
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
32923
|
Created
|
01/26/09
|
Type
|
Free
|
Moderators |
GOLDMAN SMALL CAP RESEARCH REPORT AUTHORIZED: 5,000,000,000 OUTSTANDING: 1,276,240,706 RESTRICTED: 255,174,312 UNRESTRICTED: 1,021,066,394
KALI'S NEW BUSINESS PLAN With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali will now concentrate on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali will also concentrate on the development of health and wellness therapies. The cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029. The cannabis concentrates for wellness, edibles, and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022. Prior to the acquisition by Kali, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives. As an example, and as a preview of an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of a cannabis therapy derived from Kali’s patented extraction process for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali’s patented extraction process is anticipated to be published soon. NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs. Preclinical Research Study Results on Therapy for Respiratory Disease (COPD and Asthma) Below is a link to research recently conducted by Professor Jeffrey Osborn, President of Biomedical Science Research Group, LLC, and Biology Professor at the University of Kentucky Final Report for Pilot Study - NCMB-1 (aka Blue Dream)
LETTER TO SHAREHOLDERS FROM INCOMING CEO FREDERICK FERRI - NOVEMBER 27, 2018 Dear Kali Shareholders – |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |